Developing bioelectronic medical treatments
BioSig operates in the field of bioelectronic medicine, a relatively new and growing field that focuses on how targeted electrical signals in the body can help diagnose and treat a wide range of diseases. BioSig”™s initial focus is on heart disease, specifically atrial fibrillation (AFib) or irregular heartbeat.
Founder and CEO Ken Londoner created BioSig in Los Angeles in 2009 to address what many see as shortcomings in electrophysiology (EP) technology in operating rooms; namely, that many existing systems are outdated. Since that time, BioSig has developed a first-of-its-kind technology, Pure EP, which received U.S. Food and Drug Administration market clearance in 2018.
The company is now located in Westport, where it moved in 2018. Over the summer, it moved from 54 Wilton Road to 385 Riverside Ave., and it has expanded its workforce throughout the year. It is also looking to expand beyond AFib ”” which affects some 6 million people in the U.S. ”” to hypertension, suffered by 80 million, in the near term.
For more, visit https://www.biosig.com/
